$CBNA

Cornerstone Bancorp, Inc. Quarterly Report - June 30, 2026

Cornerstone Bancorp reported 2Q26 net income of $3.2 million, or $3.2 per diluted share, versus $2.8 million, or $2.81 per diluted share, in 2Q25. Net interest margin rose to 3.97% from 3.65%. Assets were $1.01 billion, loans $795.7 million, deposits $896.9 million, and trust and wealth assets $1.36 billion as of June 30, 2026.

Original reporting
Published Aug 4, 2026, 5:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 5:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$CBNA
Bullish
medium confidence
Mentioned
$CBNA
Relevance
7/10
alphai data visualization · based on prnewswire.com
Decision brief

The 30-second read

$CBNABullishMed
01

Why it matters

Traders can update expectations for net interest income drivers (NIM, loan yield, deposit costs) and capital strength (tangible equity, Tier 1 leverage) based on the reported quarter.

02

Market read

The report provides fresh quarterly datapoints: NIM increased to 3.97%, net income rose to $3.2M, loans grew 16% YoY, and tangible equity increased 14.3% YoY.

03

What to watch

Interest earned on interest-bearing bank accounts and securities fell sharply year over year, and correspondent-bank deposits declined as a share of assets, both of which could affect future NIM.

Relevance 7/10Novelty 7/10Timing: after-hours release today (Aug. 4, 2026)

Background

PRNewswire release summarizing Cornerstone Bancorp’s second-quarter 2026 financial highlights and balance-sheet changes as of June 30, 2026.

Company-level read

Ticker impact

$CBNABullishMedium confidence
Context

Cornerstone Bancorp reported 2Q26 results, including NIM rising to 3.97% and net income of $3.2M versus $2.8M a year ago.

Expected impact

Near-term bias modestly positive, with traders focusing on NIM sustainability and deposit funding trends.

Evidence & confidence

The release provides multiple directional datapoints (NIM up, net income up, loans up, tangible equity up) but lacks forward guidance or asset-quality/credit-loss detail that would typically drive a larger repricing.

Market effects

Regional/community bank sentiment may improve modestly if NIM and loan growth trends look resilient versus funding pressure.

Chicago-area bank investors may view the report as evidence of local credit demand and deposit stability.

Low, as the disclosure is company-specific and not a macro or cross-sector shock.

Counterpoint

Loan growth may not translate into durable earnings if funding costs or credit quality deteriorate, which is not detailed here.

Key entities

  • Cornerstone Bancorp, Inc.

    Community/commercial bank reporting 2Q26 net income, NIM, balance-sheet composition, and trust/wealth AUM.

  • Cornerstone National Bank & Trust Company

    Wholly owned subsidiary referenced in the release.

Related articles

$CBNAMed

CHAIN BRIDGE BANCORP INC (CBNA): Results of Operations and Financial Condition

CHAIN BRIDGE BANCORP INC (CBNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cbna-earningsreleasexex991.htm EX-99.1 Document Exhibit 99.1 Chain Bridge Bancorp, Inc. Reports Second Quarter 2026 Financial Results McLean, Virginia — July 28, 2026 Chain Bridge Bancorp, Inc. (NYSE: CBNA) (the “Company”), the holding company for Chain Bridge Bank, N.A

$MNDYHighAI 8/10

Why Monday.com Stock Popped in August

Monday.com (MNDY) stock rose 16% in August, despite initial investor concerns over its Q2 results. Revenue grew 22% YoY to $365M, and adjusted net income increased 13% to $65.6M. The company provided optimistic guidance for Q3 and 2026. A strong earnings report from Salesforce later in the month boosted investor sentiment in the CRM sector, benefiting Monday.com.

$AQSTMed

Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus

Aquestive Therapeutics (AQST) reported Q2 2026 results, staying on track to resubmit Anaphylm epinephrine film to the FDA in Q3 2026. Studies addressed FDA concerns, with improved packaging and labeling. Revenue rose 38% to $13.8M, but net loss widened to $22.9M. Cash reserves stand at $98.5M. The company also advanced its epinephrine prodrug platform and manufacturing business.

$CRMDMedAI 8/10

CorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely Budged

CorMedix (CRMD) reported Q2 revenue of $101.9M, up from $39.7M a year ago, with net income of $26M. Management raised adjusted EBITDA guidance but kept full-year revenue guidance unchanged. DefenCath and the Melinta portfolio drove growth, with new supply agreements signed. The company expects to submit an sNDA for REZZAYO in Q3. Operating expenses increased due to Melinta's costs and R&D spending. Hedge fund ownership rose, while short interest remained high at 22.30%.

$CCSIMed

Consensus Cloud’s (CCSI) Buyback Doubles, But Growth Has A Catch

Consensus Cloud Solutions (CCSI) reported Q2 revenue of $91.4M, up 4.1%, and net income of $27.4M, up 31.7%. The board doubled its buyback authorization to $200M. Corporate segment revenue rose 9.3%, while the SoHo business declined 4.7%. Adjusted EBITDA was flat at $48.3M. The company reaffirmed its 2026 guidance and issued steady Q3 guidance.